The general targets for adults with type 2 diabetes are: Pre-meal glucose : 47 mmol/L Fasting plasma glucose : 57 mmol/L Post-prandial glucose (2 hours after meals): less than 8.5 mmol/L HbA1c : individualised, but typically 4853 mmol/mol (6.57.0%) for most adults These targets may be adjusted based on individual circumstances, including age, comorbidities, and hypoglycaemia awareness
Under separate clinical trials, Zepbound produced a 72-week median weight loss of 19 to 20%, whereas Wegovy demonstrated 14 to 15%
Week 1 to 2: Redness subsides
While it is believed that semaglutide leads to gastrointestinal disorders less than 5% of the time, transient, mild-to-moderate bouts of the following issues are commonplace among GLP-1 drugs: Nausea : 44% Vomiting: 25% Diarrhea: 32% Constipation: 23% Abdominal pain: 10% Fatigue, Dizziness, Headache Clinical data does not support the idea that semaglutide directly causes dizziness, headaches, or significant fatigue